July 6, 2023 -Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s Rapidly Growing Business
TORONTO, ON – (July 6, 2023) – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David
… Read MoreMay 23, 2023 -Results from 211 Facilities Show MolecuLight Imaging is a Valuable Tool in Improving Bacterial Infection Management
TORONTO, ON – (May 23, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, announced the publication of their latest publication,
… Read MoreMay 3, 2023 -Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Revealsits Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and Milan, ITALY – (May 3, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound
… Read MoreApril 27, 2023 -Wound Care Clinicians Can Now Manage All Wound Care Documentation, MolecuLight Images and Measurements via a Robust, Scalable Cloud Platform
National Harbor, MD – April 27, 2023 – MolecuLight Corp., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announced today that the company has
… Read MoreApril 25, 2023 -Findings show that MolecuLight is an Objective and Equitable Diagnostic Technology Positioned to Help Level Racial Disparity in Wound Care Outcomes
TORONTO, ON – (April 25, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication
… Read MoreApril 19, 2023 -Successful completion of recent audit demonstrates MolecuLight’s commitment to data security
TORONTO, ON – (April 19, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced that it is in compliance with SOC 2® Type I, having successfully
… Read MoreFebruary 14, 2023 -Findings from a New Clinical Study Using MolecuLight Imaging of Diabetic Foot Ulcers Prompts New Diagnostic Terminology Enabling Proactive Infection Management
TORONTO, ON – (February 14, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication
… Read MoreDecember 6, 2022 -Article is a Follow-On to MolecuLight’s Receipt an Innovative Technology Contract from Vizient Last Year
PITTSBURGH, PA – (December 6, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is featured in Vizient’s newly released Tech Watch publication as a
… Read MoreNovember 10, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Salt Lake City, UTAH – (November 10, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.